Dosimetry in nuclear medicine therapy: Radiobiology application and results

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 2, 2011, Pages 205-221

  Strigari, L ^a   Benassi, M ^a,b   Chiesa, C ^c   Cremonesi, M ^d   Bodei, L ^d   D'Andrea, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Neoplasms; Nuclear medicine; Radiobiology

Indexed keywords

BONE MARROW TOXICITY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL GROWTH; CELL HETEROGENEITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DNA REPAIR; DOSE RESPONSE; DOSIMETRY; HYPOXIC CELL; IRRADIATION; LIVER TOXICITY; LUNG TOXICITY; MATHEMATICAL MODEL; NEPHROTOXICITY; NUCLEAR MEDICINE; PEPTIDE RECEPTOR RADIONUCLEOTIDE THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RADIOBIOLOGY; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; REVIEW; TISSUE OXYGENATION; TREATMENT RESPONSE; TUMOR VOLUME;

BONE MARROW; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY; LINEAR MODELS; LIVER; LUNG; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEAR MEDICINE; RADIOBIOLOGY; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 79957650413     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Withers HR. The four R's of Radiobiology. Adv Radiol Biol 1975;5:241-7.
2. Withers HR. Biological basis for altered fractionation schemes. Cancer 1985;55;S2086-95.
3. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73-93. (Pubitemid 30205489)
4. Fowler JF. Radiobiological aspects of low dose-rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-9. (Pubitemid 20182364)
5. Yorke ED, Wessels BW, Bradley EW, Absorbed dose averages and dose heterogeneities in radioimmunotherapy. Antibody Immunoconjugates and Radiopharmaceuticals 1991;4:623-9.
6. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871-84. (Pubitemid 26333627)
7. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JY. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 1993;20:601-10. (Pubitemid 23134010)
8. O'Donoghue JA. Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res 1996;141:77-100.
9. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005:46(Suppl):4S-12S.
10. Howell RW, Goddu SM, Rao DV Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med Phys 1998;25:37-42.
11. Howell RW, Goddu SM, Rao DV. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. J Nuc Med 1994;35:1861-9. (Pubitemid 24346813)
12. Dale RG. The application of the linear quadratic dose-effect equation to fractionated and protracted radiotherapy. Brit J Radiol 1985;58:515-28. (Pubitemid 15018411)
13. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol 1991;64:242-51.
14. 90Y-ibritumomab tiuxetan (ZEVALIN ). Eur J Nucl Med Mol Imaging 2009;36:1745-57.
15. Pacilio M, Betti M, Cicone F, Del Mastro C, Montani L, Chiacchiararelli L et al. A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90) Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2010;37:862-73.
16. Wigg DA. Applied radiobiology and bioeffect planning. Madison, WI: Medical Physics Publishing; 2001.
17. Withers HR. Biological basis of radiation therapy for cancer. Lancet 1992;339:156-9.
18. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-35.
19. Strigari L, Arcangeli G, Arcangeli S, Benassi M. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:1454-60.
20. Withers HR. Biological basis of radiation therapy for cancer. Lancet 1992;339:156-9.
21. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005;44:265-76.
22. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-8.
23. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy: equivalent uniform dose. JNM 1999;40:1337-41. (Pubitemid 29385643)
24. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 2003;18:89-97. (Pubitemid 36307470)
25. Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys 2010 [Epub ahead of print].
26. Jones LC, Hoban PW. Treatment plan comparison using equivalent uniform biologically effective dose (EUBED). Phys Med Biol 2000;45:159-70. (Pubitemid 30060666)
27. Humm JL, Roeske JC, Fisher DR, Chen GT. Microdosimetric concepts in radioimmunotherapy. Med Phys 1993;20(2 Pt 2):535-41.
28. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 1995;31:883-91.
29. Strigari L, D'Andrea M, Maini CL, Sciuto R, Benassi M. Biological optimization of heterogeneous dose distributions in systemic radiotherapy. Med Phys 2006;33:1857-66. (Pubitemid 43830274)
30. 90Y. Radiother Oncol 1991;21:91-9.
31. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-9.
32. Botta F, Cremonesi M, Di Dia A, Ferrari M, Valente M, De Cicco C et al. 90Y, 177Lu, and 1311 therapy optimisation: Monte Carlo calculation of dose distribution and radiobiological evaluations. J Nucl Med 2009;50 (Suppl. 2):1859.
33. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41. (Pubitemid 13008961)
34. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6.
35. 131I. Phys Med Biol 2005;50:2181-91.
36. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):92S-8S.
37. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol 2008;53:6591-603.
38. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: Radiobiologic considerations. J Nucl Med 2010;51:1377-85.
39. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005;26:731-5. (Pubitemid 41073376)
40. Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 1311 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;4:619-25. (Pubitemid 47618592)
41. Canzi C, Zito F, Voltini F, Reschini E, Gerundini P. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys 2006;33:2860-7. (Pubitemid 44154557)
42. Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D et al. Hepatic absorbed radiation dosimetry during 1-131Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging 2008;35:2105-12.
43. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med 2008;49:1884-99.
44. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S-106S.
45. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177LU-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-56.
46. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112:1538-46. (Pubitemid 351441166)
47. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M; EANM Dosimetry Committee. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405-12.
48. Traino AC, Ferrari M, Cremonesi M, Stabin M. Influence of total-body mass on scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol 2007;52:5231-48. (Pubitemid 350153386)
49. Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90) Y-antibody therapy. J Nucl Med 2002;43:1245-53. (Pubitemid 34988774)
50. Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer 2010;116(4 Suppl):1093-100.
51. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol 1962;87:171-82.
52. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451-6. (Pubitemid 39586024)
53. Lee JJ, Chung JK, Kim SE, Kang WJ, Park Do J, Lee DS et al. Maximal safe dose of 1-131 after failure of standard fixed dose therapyin patients with differentiated thyroid carcinoma. Ann Nucl Med 2008;22:727-34.
54. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC et al. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2010;37:896-903.
55. Lassmann M, Hänscheid H, Gassen D, Biko J, Meineke V, Reiners C et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010;51:1318-25.
56. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging 2010;54:100-13.
57. Barendswaard EC, O'Donoghue JA, Larson SM, Tschmelitsch J, Welt S, Finn RD. Humm JL 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J Nucl Med 1999;40:1764-8.
58. Feinendegen LE, Neumann RD. Dosimetry and risk from low-versus high-LET radiation of Auger events and the role of nuclide carriers. Int J Radiat Biol 2004;80:813-22.
59. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi Rule. J Nucl Med 2006;47:1977-84.
60. Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 2006;47:1985-94.
61. SIR-Spheres Yttrium-90 microspheres (package insert). Lane Cove, Australia: Sirtex Medical; 2004.
62. Chua TC, Saxena A, Chu F, Butler SP, Quinn RJ, Glenn D et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol 2010 [Epub ahead of print].
63. Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, Bilbao JI, Arbizu J, Benito A et al. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;77:1441-8.
64. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology 2010;138:52-64.
65. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16(2 Pt 1):205-13.
66. Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumors. Eur J Nucl Med 1996;23:947-52.
67. Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D et al. Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging 2008;35:2088-96.
68. Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D'Asseler Y. (99m)Tc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with (90)Y microspheres. Eur J Nucl Med Mol Imaging 2010;37:2328-33.
69. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C et al. The significance of 99mTc-MAA SPECT/ CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010;51:1206-12.
70. Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S. Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat 2010;9:253-62.
71. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA et al. Radiolabeled somatostatin analog (177Lu-DOTA0,Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
72. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103, 2007.
73. Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009;50:1605-10.
74. Strigari L, Sciuto R, Benassi M, Bergomi S, Nocentini S, Maini CL. A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism. Med Phys 2008;35:3903-10.
75. Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2010 [Epub ahead of print].
76. Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009;53:546-61.
77. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G; EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238-50.
78. 131I therapy on survival of patients with metastatic papillary or folliculary thyroid carcinoma. J Clin Endocrinol Metab 1973;36:1143-52.
79. Hartmann Siantar CL, Vetter K, DeNardo GL, DeNardo SJ. Treatment planning for molecular targeted radionuclide therapy. Cancer Biother Radiopharm 2002;17:267-80.
80. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med 2007;48:1683-91.
81. Lassmann M, Strigari L, Bardiès M. Dosimetry is alive and well. Cancer Biother Radiopharm 2010;25:593-5.